HE rationale for the therapeutic use of sympathomimetic amines in patients with shock is disputed. Nickerson, citing experimental studies in animals and clinical observations, has favored the view that increased adrenergic vasoconstriction resulting from such therapy potentiates shock.1 2 Lillehei, Longerbeam, and their co-workers3' 4 reported that norepinephrine administered to dogs made hypotensive with endotoxin leads to reduction in visceral blood flow. Except in terminal stages, most types of shock are not attended by a decrease in arterial resistance.5-8 Circulating levels of endogenous adrenal medullary secretions have been shown to increase, especially during initial stages of shock; their significance in relation to vascular reactivity, however, remains to be clarified.9 Adrenal medullary insufficiency may occur in severe shock.'0
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The above-mentioned observations have supported the common assumption that elevation of blood pressure achieved after the use of pressor amines in p-atients with shock must result at the expense of a reduction in cardiac output. Objective studies on the hemodynamic effects of sympathomimetic drugs in patients with acute hypotension, however, are scanty." In the present investigation such measurements were made during treatment of 19 In the latter group gram-negative bacteria were recovered on blood cultures in five patients (nos. 8, 9, 10, 11, and 12). One patient wals in shock following an overdosage of barbiturates (no. 18), and another after intoxication with chlorpromazine (no. 19) . In 14 of the patients vasopressor agents had been administered some time prior to admission to the Shock Ward. All therapy was discontinued at the beginning of our study until the blood pressure had stabilized. B-aseline recordings for most patients included at least two determinations of cardiac output. These control measurements were made J2 to 4 hours after discontinuance of vasopressor therapy in all but one patient. In this patient (no. 1) the vasopressor agent was restarted after 18 minutes because the mean arterial pressure fell rapidly to levels below 40 mm. Hg. The clinical features of acute hypotension and shock were clearly present in 15 of the 19 patients at the time of the study. In addition to hypotension, these patients had clouded sensorium, oliguria, and pallor of the skin and mucous membranes. In four patients (nos. 9, 11, 14, and 16) the clinical features of shock had partly subsided. Circulation, Volumne XXX, OctobJer 1964 Metaraminol bitartrate,* in a dilution of 200 mg. per liter of water containing 5 per cent glucose, was infused into a large arm vein in 17 patients. In two patients levarterenol,t in dilution of 4 mg. per liter, was given in a corresponding manner. Cardiac output was recorded twice, usually at 15 minutes and at 30 minutes, during a control period, and at two or more higher levels of arterial pressure produced by administration of increasing amounts of the vasopressor amine.
Methods Intravascular pressures were measured by strain-gauge manometers (Statham 23 AA) and recorded on a direct-writing multichannel recorder (Sanborn 350 System). Arterial pressure was recorded through an 18-gauge Cournand needle inserted into the brachial or femoral artery. Central venous pressure was recorded in 11 patients through a polyvinyl catheter (PE 190), 80 cm. in length, advanced through a percutaneous needle puncture of the basilic vein into the superior vena cava. In eight patients the venous pressure was recorded in the femoral vein.
Cardiac output was quantified by the dye-dilution technic of Nicholson and Wood,12 with injection of indocyanine green dye into the venous catheter or needle. A Gilford photoelectric densitometer was used, and recordings were made on the Sanborn system. The recorded dye curves were analyzed by digital integration and logarithmic extrapolation, according to the method of Hamilton et al. 13 Peripheral vascular resistance, stroke volume, and mean circulation time were calculated by standard formulas.'4 The pH of arterial blood was measured with a Beckman expanded scale pH meter and a blood microelectrode, with an accuracy of ± 0.01 pH unit. The Severinghaus electrode was employed in con-Junction with the Beckman expanded pH meter for measurement of pCO2, with an accuracy of + 2 mm. pCO2.
Results
Following administration of the vasopressor amine, the total increase in arterial pressure averaged 55 per cent (62 to 96 mm. Hg). The cardiac index increased from 2.0 to 2.3 L./min./M.2 (S.E.D. =0.418 p <0.01). It should be noted that the mean figure for cardiac index during the control period is not representative of the entire group. In the four patients who had at least partially recovered at the time of our study (nos. 9, 11, 14, and 16), the cardiac index was within normal limits. In two patients (nos. 17 and 19) , chlorpromazine intoxication and the anemia accompanying the chronic lymphatic leukemia may have accounted for a higher cardiac output. In 10 of the 13 remaining patients with acute hypotension and clinical features of shock, the control cardiac index was markedly diminished (table 2) .
Changes in hemodynamic functions at increasing levels of arterial pressure produced by vasopressor amine in the case with most severe hypotension are depicted in figure 1 .
The observed increase in cardic.e index exceeded 15 per cent of its initial value in 13 patients and 20 per cent in 11 patients. In five patients no significant increase in cardiac index was demonstrated (< 10 per cent). Only one patient (no. 10) had a progressive decline in cardiac output during infusion of metaraminol. No explanation was apparent for this single observation in a patient with bac- Hemodynamic changes following infusion of levarterenol in a patient with hemorrhagic pancreatitis (B.K.) and severe hypotension. V.P., central venous pressure; C.l., cardiac index; M.C.T., mean circulation time; C.B.V., central blood volume. terial shock. In two additional cases (nos. 16 and 17) paradoxical reduction in cardiac output was seen following the initial or subsequent dose of metaraminol. The change in cardiac index at increasing arterial pressure levels in 14 patients is graphically shown in figure 2 . Not shown are the five cases in which no significant change in cardiac output occurred. A modest rise in central venous pressure usually followed infusion of vasopressor agent. With higher doses of the pressor amine, more pronounced increases were observed (table 2). The related changes in the mean circulation time were examined. When vasopressor agent produced a significant increase in cardiac output, a decrease in mean circulation time was observed in a majority of the patients. An example is shown graphically in figure 1 . Conversely, when a pressor response was not accompanied by an increase in cardiac output, the mean circulation time was prolonged in all but one of 12 observations. Because of the known significance of blood pH and pCO2 in the pressor response Circulation, Volume XXX, October 1964 to vasopressor drugs,1'5 16 these functions were measured in all patients. The pH ranged from 7.32 to 7.55 units, and pCO2 from 22 to 65 mm. No direct relation was established in this study between pH, pCO2 and effect of the vasopressor amine on cardiac output.
The possibility that the observed increases in cardiac output may be separated from a predominant vasoconstrictive effect was also investigated. The increase in cardiac output occurred over a relatively narrow range of pressure elevation. When mean arterial pressure was increased to levels above 90 mm., no additional improvement in cardiac output was found. This is illustrated in figure 3 . The average of blood pressures obtained during the control period, prior to treatment with vasopressor agent, was 62 mm. Hg. After the initial infusion of the vasopressor agent and elevation of arterial pressure to a mean value of 89 mm. Hg, a significant increase in cardiac output occurred. Since significant changes did not occur in the heart rate, the mean change in cardiac output is shown in figure 3 as stroke volume related to arterial pressure. The variation in individual responses is also shown in the figure, in which the shaded area represents one standard error at each of the arterial pressure values.
Discussion
The present studies in patients with hypo- Changes in stroke volume and one standard error (S.E.) following infusion of vasopressor amine, based on study of 19 patients. tension show that the pressor effect of sympathomimetic amines is initially accompanied by a modest increase in cardiac output. Although this increase chiefly occurs at moderate elevations of arterial pressure, yet it is maintained in the face of increasing peripheral resistance at higher levels of arterial pressure. Similar observations have been made in experimental animals in which shock was produced by bleeding 17 or by bacterial endotoxin.'8 Only one of 19 patients had a progressive fall in cardiac output. These observations have theoretical and practical implications. If the vasoconstrictor effect predominates, it is hypothesized by some that there would be a concomitant reduction in total blood flow through constricted arterioles and, possibly, constricted venules and veins. To the contrary, the present study indicates that the cardiac output which represents gross systemic blood flow was clearly not decreased. This, then, is evidence against the thesis that vasopressor drugs must ca.use vasoconstriction to the extent that venous return and, therefore, cardiac output are reduced. In concluding that venous return and cardiac output are not reduced by vasopressor amine, the possibility of unfavorable changes in "effective" blood flow are not excluded. A significant reduction in perfusion of some tissues may exist without a fall in cardiac output. It should be recognized that the peripheral distribution of increased total vascular resistance produced by the pressor amine may enclose vascular beds such as the heart, skeletal muscle, and brain, in which resistance is actually decreased. Blood flow through high resistance beds, such as the intestine and kidney, may in fact be curtailed, as shown in experimental animals.4 19'20 Controlled studies in patients on regional distribution of the systemic blood flow are needed, as the difficulty of extrapolating from observations on animal models is well known.21 22 However, the evidence at hand does not justify the concept that clinical use of vasopressor drugs produces a net reduction in systemic blood flow.
A pertinent consideration is validation of the technics used for measurement of cardiac output. We are concerned with the validity of the dye-dilution method in patients with hypotension, particularly when there is a profound reduction in cardiac output. In a mechanical model of the circulation, as well as in an intact dog on right heart bypass, the flow calculated from dye-dilution curves was valid at low flow rates. 23 In hemorrhagic shock, the changes in cardiac output measured with the Fick technic were confirmed by the dye-dilution method.24, 25 Alteration of resistance and capacitance in the circuit were later shown not to invalidate the measurement of cardiac output by indicator-dilution method.26 Indicator-dilution technics have since been widely used for measurement of cardiac output during shock in animals24 2527 and, more recently, in patients.6
The accuracy and reproducibility of this method are also an issue, particularly since the changes in cardiac output herein reported are small. For this reason, separate analysis was made of 105 serial measurements by our technic obtained from 18 unselected normotensive subjects, some of whom were in congestive heart failure. Cardiac output ranged from 1.0 to 7.6, with an average of 4.0 L./min. The standard error of the difference between serial determinations and the mean value in each subject was ± 9 per cent (S.D. 0.36, S.E.M. 0.035), and the standard error of the differences between two contiguously paired observations lin the same patient was 13 per cent. These findings are in good agreement with published reports of reproducibility of the indicator-dilution technics.28
The mechanism by which vasopressor amines produce an increase in cardiac output in patients who are in shock is not clarified in the present study. However, experimental evidence implicates both myocardial and peripheral vascular effects.
In studying the myocardial effects of metaraminol in dogs, Sarnoff and his co-workers29 found that this vasopressor drug, when administered in amounts too small for Circulation, Volume XXX, October 1964 elevation in peripheral vascular resistance, clearly improved myocardial contractility. The vasoconstrictor and myocardial effects were separate and disassociated. Their studies also suggested that the duration of the myocardial effect of catecholamines might outlast their effect on the resistance vessels.
The mechanism by which cardiac output is increased may also involve effects of sympathomimetic amines on venous vessels. Important differences in the effect of sympathomimetic amines on arterial (resistance) and venous (capacitance) vessels have been reviewed by Folkow.30 Mobilization of venous pools, either by local dilatation at a venous outflow site, especially in the splanchnic bed, or venous compression by which inactive venous pools are reduced, may contribute to the increase in cardiac output. 31 Experimental evidence for such a mechanism is at hand in connection with studies on acute endotoxic shock.'8 The modest rise in venous pressure associated with the use of vasopressor amines in patients in the present series may be in keeping with this evidence, but it may also reflect an increase in right ventricular enddiastolic pressure. The changes in circulation time were not consistent enough to be conclusive. While effects on the myocardium and the venous circuit would fully explain the observed changes, definitive evidence requires studies in which myocardial, arterial, and venous effects are separated.
The present study was designed to explore changes in cardiac output. The peripheral distribution of the observed increase in cardiac output is not as yet defined. Until this is known, it is not possible to say that the increase in cardiac output is, of itself, beneficial. As a starting point, however, we conclude from the present studies that increased vasoconstriction resulting from the use of vasopressor amines in shock does not curtail the total blood flow to the extent that cardiac output or the systemic blood flow is reduced; to the contrary, it is usually increased.
Summary and Conclusions
Intra-arterial pressure, central venous pres-Circulation, Volume XXX, October 1964 sure, and cardiac output were recorded in 14 patients with acute hypotension (shock), and five patients during recovery from shock. Metaraminol and levarterenol were administered by intravenous infusion, and serial measurements of these hemodynamic variables were made. Despite increases in total peripheral resistance, a decrease in cardiac output after infusion of vasopressor agents was observed in only one patient.
With moderate elevations of arterial pressure, cardiac output was increased. With further elevation of arterial pressure, no additional increase in cardiac output was detected, but neither was a decline observed. These observations do not support the contention that vasopressor amines, through their vasoconstrictor effect, reduce the total systemic blood flow when used for the treatment of shock in man.
